Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- Excluding AL amyloidosis is the key early branch point before ATTR-CM is treated as established.
- AL can mimic ATTR-CM clinically and on imaging while changing both prognosis and diagnostic logic.
- Monoclonal testing reshapes how imaging is interpreted, not just whether it’s ordered.
- Abnormal or discordant results warrant hematology involvement and amyloid typing rather than an imaging-only diagnosis.
Why AL Exclusion Is the Decisive Branch Point
The differential diagnosis of ATTR-CM is challenging because the phenotype overlaps with hypertensive heart disease, aortic stenosis, hypertrophic cardiomyopathy, and ischemic disease. However, the diagnosis that most changes management is AL amyloidosis.. AL amyloidosis can look similar clinically and on imaging while carrying a different prognosis and a more urgent treatment pathway, so excluding it is the decisive early branch point before ATTR-CM is treated as established. The suspicion that gets a patient to this branch comes from the clustered clues that are described in pattern recognition and exclusion logic.
How Monoclonal Testing Changes Imaging Interpretation
Monoclonal protein assessment does more than add a test; it changes how the imaging results should be interpreted. Serum free light chain testing together with serum and urine immunofixation electrophoresis determine whether an imaging-led ATTR pathway remains credible. With a negative monoclonal screen and a compatible phenotype, a positive bone-avid scan strongly supports ATTR-CM. However, if any test is abnormal, the same positive scan cannot exclude AL amyloidosis and may even reflect it. That’s why 99mTc-PYP scintigraphy is interpreted in the context of monoclonal test results, not in isolation.
When to Involve Hematology and Pursue Amyloid Typing
When monoclonal studies are abnormal, equivocal, or discordant with the phenotype, further evaluation should include hematology consultation and tissue biopsy with amyloid typing rather than relying on an imaging-only ATTR diagnosis. Mixed disease is possible, particularly in older patients in whom an incidental monoclonal gammopathy can coexist with ATTR, so a positive monoclonal result doesn’t by itself exclude ATTR-CM. Coordinating that step is often where a specialized amyloidosis center adds the most value, and it feeds directly into how the workup is sequenced.
Clinical Decision Point
The decision is not simply "ATTR or not" but "has AL amyloidosis been excluded confidently enough to proceed." A negative monoclonal screen with a concordant phenotype and bone-avid scan supports a nonbiopsy ATTR diagnosis. Any abnormal light-chain or immunofixation result, an aggressive or atypical course, or discordant findings should prompt hematology referral and tissue typing before establishing a definitive diagnosis of ATTR-CM.
Frequently Asked Questions
Why is AL amyloidosis the key early exclusion in ATTR-CM?
Since AL can mimic ATTR-CM clinically and on imaging while carrying a different prognosis and a more urgent treatment pathway, confirming or excluding it changes both diagnostic logic and management.
Does a positive bone-avid scan rule out AL amyloidosis?
No. A positive scan supports ATTR-CM only when AL has been excluded with monoclonal testing. AL can show myocardial uptake, so the scan must be read together with serum free light chains and immunofixation electrophoresis.
When should hematology be involved?
When monoclonal studies are abnormal or equivocal, when the course is unexpectedly aggressive, or when findings are discordant., these situations necessitate tissue typing rather than an imaging-only diagnosis.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.